<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03324867</url>
  </required_header>
  <id_info>
    <org_study_id>2018-3964</org_study_id>
    <nct_id>NCT03324867</nct_id>
  </id_info>
  <brief_title>The Effect of Intranasal Insulin Administration on Cognitive Function After Cardiac Surgery.</brief_title>
  <official_title>The Effect of Intranasal Insulin Administration on Cognitive Function After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Decline in cognitive function after surgery occurs most commonly in older patients and
      patients undergoing major surgeries, such as heart surgery. Postoperative Cognitive
      Dysfunction (POCD) may last a prolonged period of time while Postoperative Delirium (POD) is
      a more acute disturbance in attention, awareness and cognition. The cause of POCD and POD are
      not fully understood, however some of the pathophysiology of POCD is similar to that of
      Alzheimer's disease (AD).

      Insulin given intravenously during heart surgery has been shown to preserve short and
      long-term memory function after the operation. Clinical trials further demonstrated that
      insulin given via the nose (intranasal) improves memory performance of patients with AD or
      cognitive impairment suggests that intranasal insulin also could be a therapeutic option for
      POCD and POD.

      This study is designed to examine the effect intranasal insulin on POCD and POD. The goal is
      to investigate whether administration of intranasal insulin during and after heart surgery
      improves cognitive function postoperatively.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confusion Assessment method for the ICU</measure>
    <time_frame>an average of 5 days</time_frame>
    <description>Post Operative Delirium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rey Auditory Verbal Leaning</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Episodic Memory Lowest score: 0 Highest Score: 15</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rey-Osterrieth Complex Figure Test:</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Episodic Memory Lowest score: 0 Highest Score: 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stropp Test</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Executive Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail Making Test</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Executive Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tower of London test</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Executive Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symbol Digit Modalities Test</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Information Processing Speed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Boston Naming Test</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Language Lowest score: 0 Highest score: 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clock Drawing Test</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Visuospatial Function Lowest score: 1 Highest score: 10</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Cognitive Decline</condition>
  <condition>Heart Diseases</condition>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>Intranasal Insulin 40 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 IU of Humulin-R via nose Before surgery and everyday after surgery up to POD 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline via nose Before surgery and everyday after surgery up to POD 7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular insulin</intervention_name>
    <description>40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.</description>
    <arm_group_label>Intranasal Insulin 40 IU</arm_group_label>
    <other_name>Humulin R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline Flush, 0.9% Injectable Solution</intervention_name>
    <description>Placebo: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery</description>
    <arm_group_label>Intranasal Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ elective open heart surgery requiring cardiopulmonary bypass

        Exclusion Criteria:

          -  inability to provide informed consent

          -  allergy to insulin

          -  pregnancy

          -  mother tongue other than English or French

          -  visual or hearing impairment interfering with the ability to complete cognitive tests.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Schricker, M.D., PhD.</last_name>
    <phone>5149341934</phone>
    <email>thomas.schricker@mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hiroaki Sato, M.D., PhD.</last_name>
    <phone>5149341934</phone>
    <phone_ext>64275</phone_ext>
    <email>hiroaki.sato2@mcgill.ca</email>
  </overall_contact_backup>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Center</investigator_affiliation>
    <investigator_full_name>Hiroaki Sato, MD., PhD.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

